Focused On-demand Library for Carboxypeptidase A1

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
P15085

UPID:
CBPA1_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P15085; A4D1M1; Q53XU0; Q9BS67; Q9UCF2

BACKGROUND:
Carboxypeptidase A1, identified by the unique identifier P15085, is a specialized enzyme that facilitates the hydrolysis of terminal amino acids in peptide chains, with specificity towards certain residues. This enzyme's action on leukotriene C4 further signifies its role in inflammatory processes.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Carboxypeptidase A1 offers a promising avenue for the development of novel therapeutic approaches. Given its enzymatic activity and specificity, targeting this protein could lead to innovative treatments for diseases where its pathway plays a pivotal role.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8758 of 8789